

Diasorin

LIAISON PLEX®

Bloodstream Infection Syndromic Panels

Optimize treatment in hours – not days.



BLOODSTREAM INFECTIONS



MOLECULAR SOLUTIONS

Bloodstream Infection Portfolio


For every hour that appropriate antimicrobial treatment is delayed, a patient's mortality rate due to sepsis increases by 7.6%. Additionally, prescribing incorrect or unnecessary treatment places a significant financial burden on our healthcare system.¹

The LIAISON PLEX® bloodstream infection portfolio (BSI) empowers laboratories to rapidly identify causative bacteria and yeast, including relevant resistance genes, that can lead to sepsis. These rapid results give physicians the opportunity to optimize antimicrobial treatments more quickly than with traditional culture alone. BSI assays built with Diasorin's proprietary NanoGrid Technology have been proven to complement antimicrobial stewardship programs, reduce the use of unnecessary antibiotics, and effectively manage infection control.²⁻⁴

The LIAISON PLEX® BSI assays help:

- **Reduce over testing** by driving panel selection based on Gram stain which is already part of standard of care workflows.
- **Reduce costs** by limiting testing to the type of organism seen on Gram stain.
- **Drive optimized treatment decisions sooner** by delivering results in approximately 2 hours after Gram stain of a positive blood culture.

Time to results is 3x faster compared to traditional methods.⁵



The LIAISON PLEX® sample-to-answer platform delivers results in about 14.5 hours versus 48 hours for conventional methods.⁵ Clinical studies have demonstrated that bloodstream infection assays using our proprietary NanoGrid Technology lower overall healthcare costs, shorten the patient's length of stay, and most importantly, improve patient outcomes by enabling a more targeted treatment plan—sooner.⁶⁻⁹



Clinically Relevant

Improve clinical outcomes and support antimicrobial stewardship.



Economically Responsible

Reduce patient length-of-stay and save costs beyond the laboratory.



Operationally Efficient

Deliver timely, actionable results.

Syndromic Testing

Panels designed to support your diagnostic and antimicrobial stewardship programs

LIAISON PLEX® bloodstream infection assays provide the flexibility to only test for clinically relevant targets based on Gram stain of a positive blood culture. This approach offers the advantage of choosing your panel based on pathogen morphology, thereby lowering costs by eliminating testing for bacteria and/or yeast ruled out by Gram stain.



LIAISON PLEX® Yeast Blood Culture Assay

Fungal Targets

<i>Candida albicans</i>	<i>Candida kefyr</i>
<i>Candida auris</i>	<i>Candida krusei</i>
<i>Candida dubliniensis</i>	<i>Candida lipolytica</i>
<i>Candida famata</i>	<i>Candida lusitanae</i>
<i>Candida glabrata</i>	<i>Candida parapsilosis</i>
<i>Candida guilliermondii</i>	<i>Candida tropicalis</i>
<i>Candida haemulonii</i> / <i>C. duobushaemulonii</i>	<i>Cryptococcus neoformans</i> / <i>C. gattii</i>

LIAISON PLEX® Gram-Negative Blood Culture Assay

Bacterial Targets

<i>Acinetobacter</i> spp.	<i>Klebsiella variicola</i>
<i>Acinetobacter baumannii</i>	<i>Morganella morganii</i>
<i>Citrobacter</i> spp.	<i>Neisseria meningitidis</i>
<i>Enterobacter</i> spp.	<i>Proteus</i> spp.
<i>Enterobacteriaceae</i> / <i>Morganellaceae</i>	<i>Pseudomonas</i> spp.
<i>Escherichia coli</i>	<i>Pseudomonas aeruginosa</i>
<i>Haemophilus influenzae</i>	<i>Salmonella</i> spp.
<i>Klebsiella oxytoca</i>	<i>Serratia marcescens</i>
<i>Klebsiella pneumoniae</i>	<i>Stenotrophomonas maltophilia</i>

Gram-Negative Resistance Genes

CTX-M	OXA
IMP	SME
KPC	VIM
NDM	MCR

LIAISON PLEX® Gram-Positive Blood Culture Assay

Bacterial Targets

<i>Bacillus</i> spp.	<i>Staphylococcus lugdunensis</i>
<i>Enterococcus faecalis</i>	<i>Streptococcus</i> spp.
<i>Enterococcus faecium</i>	<i>Streptococcus agalactiae</i>
<i>Listeria</i> spp.	<i>Streptococcus anginosus</i> group
<i>Staphylococcus</i> spp.	<i>Streptococcus pneumoniae</i>
<i>Staphylococcus aureus</i>	<i>Streptococcus pyogenes</i>
<i>Staphylococcus epidermidis</i>	

Gram-Positive Resistance Genes

<i>mecA/mecC</i>
<i>vanA</i>
<i>vanB</i>

Your comprehensive portfolio for bloodstream infection testing

Ordering Information

<i>Description</i>	<i>Kit Components</i>	<i>Part Number</i>
LIAISON PLEX® Gram-Negative Blood Culture Assay	12 Assay Cartridges 15 Transfer Pipettes	20-005-303
LIAISON PLEX® Gram-Positive Blood Culture Assay	12 Assay Cartridges 15 Transfer Pipettes	20-005-305
LIAISON PLEX® Yeast Blood Culture Assay	12 Assay Cartridges 15 Transfer Pipettes	20-005-306

REFERENCES:

1. Weiss S, Fitzgerald J, Balamuth F, et al. Delayed Antimicrobial Therapy Increases Mortality and Organ Dysfunction Duration in Pediatric Sepsis. Crit Care Med. 42(11):2409-2417. doi: 10.1097/CCM.000000000000050. 2. Rivard K, Athans V, Lam S, et al. Impact of antimicrobial stewardship and rapid microarray testing on patients with Gram-negative bacteremia. Eur J Clin Microbiol Infect Dis. 2017 Oct;36(10):1879-87. doi: 10.1007/s10096-017-3008-6. 3. Box M, Sullivan E, Ortwine K, et al. Outcomes of rapid identification for Gram-positive bacteremia in combination with antibiotic stewardship at a community-based hospital system. Pharmacotherapy. 2015; 35(3): 269-276. 4. Walker T, Dumadag S, Lee C, et al. Clinical impact of laboratory implementation of VERIGENE BC-GN microarray-based assay for detection of gram-negative bacteria in positive blood cultures. J Clin Microbiol. 2016 Jul;54(7):1789 – 96. 5. Felsenstein S, Mender J, Spoto R, et al. Impact of a rapid blood culture assay for gram-positive identification and detection of resistance markers in a pediatric hospital. Arch Pathol Lab Med. 2016;140:267-75. 6. Hill JT, Tran KD, Barton KL, et al. Evaluation of the Nanosphere Verigene BC-GN assay for direct identification of gram-negative bacilli and antibiotic resistance markers from positive blood cultures and potential impact for more-rapid antibiotic interventions. J Clin Microbiol. 2014. 52:3805-3807. doi:10.1128/JCM.01537-14. 7. Goff DA, Jankowski C, Tenover FC. Using rapid diagnostic tests to optimize antimicrobial selection in antimicrobial stewardship programs. Pharmacotherapy. 2012. 32:677-687. doi:10.1002/j.1875-9114.2012.01137. 8. Sango A, McCarter Y, Johnson D, et al. Stewardship approach for optimizing antimicrobial therapy through use of a rapid microarray assay on blood cultures positive for Enterococcus species. J Clin Microbiol. 2013. 51:4008-4011. doi:10.1128/JCM.01951-13. 9. Perez KK, Olsen RJ, Musick WL, et al. Integrating rapid pathogen identification and antimicrobial stewardship significantly decreases hospital costs. Arch Pathol Lab Med. 2013. 137:1247-1254. doi:10.5858/arpa.2012-0651-OA.

To keep up to date with the Diasorin bloodstream infection portfolio, fill out the form linked below.



Diasorin

Austin, TX
p: +1 (512) 381 4397
w: diasorin.com

<https://info.diasorin.com/clinical/bloodstream-infection-assay-interest>

For In Vitro Diagnostic Use. Products are region specific and may not be approved in some countries/regions. Please contact Luminex at support@luminexcorp.com to obtain the appropriate product information for your country of residence.

©2025 Luminex Corporation. All rights reserved. LIAISON PLEX is a trademark of Luminex Corporation and/or its affiliates, registered in the US and other countries.

BR777200.US.0625